Uveitis – Global Drug Forecast and Market Analysis to 2029
- Pages: 203
- Published: June 2021
- Report Code: GDHC223PIDR
Corticosteroids are typically the first line of therapy for most patients with uveitis as these drugs are very effective and have anti-inflammatory effects. However, as corticosteroids are associated with the development of cataracts and changes in intraocular pressures, it is becoming increasingly common for other immunosuppressants such as antimetabolites and calcineurin inhibitors to be prescribed alongside first-line treatments. Immunosuppressants suppress the inflammatory response, which is what drives uveitis. This means that 45.2% of drug sales for uveitis are expected to be generated by long-acting immunosuppressants in 2029, a rise from 28% in 2019.
Magdalene Crabbe, Senior Pharma Analyst at GlobalData, comments: “Long-acting non-steroidal drugs are the future of therapy in the uveitis space. Uveitis is characterised by ocular inflammation, and immunosuppressants can offer a quick anti-inflammatory response without the risks often associated with corticosteroids. Further, long-acting immunosuppressants work for two or more weeks.”
Uveitis drug sales in the nine major markets (9MM*) are expected to almost triple from $286m in 2019 to $790m in 2029. Sales of long-acting immunosuppressants reached $80m in 2019, and these drugs are expected to generate $357m in 2029.
While more chronic and recurrent uveitis patients will experience relief from treatment with long-acting immunosuppressants, a key issue in this therapy area is the need to develop drugs that can be administered by the patient.
Crabbe continues: “The greatest advantage of some immunosuppressants is the fact that they are inserted into the eyes, which reduces the risk of systemic side effects. This is especially important for patients with autoimmune diseases and comorbidities that negatively affect patients’ quality of life.”
*9MM: US, France, Germany, Italy, Spain, UK, Japan, Canada, and Australia
Overview of epidemiological data, including information about disease duration (acute, chronic, recurrent), localization (anterior, intermediate, posterior, or panuveitis), and etiology (non-infectious, infectious, or idiopathic).
Examination of pathophysiology, symptoms, diagnosis, and disease management.
Annualized forecast of sales of uveitis therapeutics in the 9MM.
Examination of unmet needs, ongoing clinical trials, and profiles of individual marketed drugs.
Assessment of pipeline drugs, including clinical and commercial aspects of each therapy in development for the treatment of uveitis in adults.
Review of key market drivers and barriers.
Discussion of market potential and opportunities for drug developers in the uveitis space.
Key Questions Answered in This Report
– What were the market leading drugs for uveitis in 2019?
– When will the late-stage pipeline products launch in each of the 9MM?
– What are the major clinical and environmental unmet needs in the uveitis market?
– What are the key commercial opportunities for pharmaceutical companies developing therapies for uveitis?
- Drugs for non-infectious uveitis generated an estimated $286.3M in 2019, across the 9MM. GlobalData projects that the market will expand at a Compound Annual Growth Rate (CAGR) of 10.7%, reaching $789.7M in 2029.
- Corticosteroids and immunosuppressants such as methotrexate, azathioprine, and tacrolimus are frequently used to treat patients with uveitis. The main issue with corticosteroids is their potential to cause elevated intraocular pressures and cataracts. Most patients develop these complications after long-term treatment with steroids.
- Immunosuppressants such as azathioprine and tacrolimus take several weeks to bring about therapeutic outcomes. Humira (adalimumab) was the first biologic to gain approval for the treatment of uveitis. However, the drug is injected subcutaneously, and this has been linked to dermatological side effects and discomfort.
- Anterior uveitis makes up the majority of diagnosed prevalent cases of the disease. However, symptoms can overlap with conjunctivitis and keratitis. This can lead to misdiagnosis and delayed initiation of effective treatment.
- A number of drugs that are being developed for uveitis are also in the pipeline for other inflammatory diseases. This is useful because a significant percentage of patients with non-infectious uveitis also have an immune system-related comorbidity.
- Factors that will contribute to growth in the market include continued use of AbbVie’s Humira for the treatment of both anterior and posterior uveitis, the introduction of non-steroidal therapies for the management of patients with anterior uveitis, and the assumed increase in the number of people who develop recurrent uveitis in line with the growing prevalence of autoimmune conditions.
- Barriers to growth include the use of inexpensive generic formulations of immunosuppressants in all of the 9MM and lack of compliance among patients who are instructed to apply eye drops up to six times per day.
- The top-selling late-stage pipeline agent in 2029 will be EYS-606. This is because the drug is expected to be the only gene therapy that will become available to treat anterior uveitis during the forecast window.
Reasons to buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the uveitis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the uveitis therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Johnson & Johnson
Bausch & Lomb
Mitsubishi Tanabe Pharma
Table of Contents
Table of Contents
| About GlobalData
1 Uveitis: Executive Summary
1.1 The Uveitis Market Will Almost Triple In Size from 2019-2029
1.2 Steroid-Sparing Immunosuppressive Strategies Increasingly Favored by Clinicians and Patients
1.3 Lack of Novel Therapies for Anterior Uveitis Will Limit Market Growth in Japan, Canada, and Australia
1.4 Strategic Alliances Are a Key Priority for Drug Developers in This Therapy Area
1.5 Focus Is On Label Expansion and Treatment of Comorbidities in the Uveitis Pipeline
1.6 What Do Physicians Think?
2.2 Related Reports
2.3 Upcoming Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Classification or Staging Systems
3.3 Prognosis and Quality of Life
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global and Historical Trends
4.4 9MM Forecast Methodology
4.4.2 Forecast Assumptions and Methods
4.4.3 Forecast Assumptions and Methods: Diagnosed Incident and Diagnosed Prevalent Cases of Uveitis – 9MM
4.4.4 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation
4.4.5 Diagnosed Prevalent Cases of Uveitis by Etiology
4.4.6 Diagnosed Prevalent Cases of Uveitis by Severity
4.4.7 Diagnosed Prevalent Cases of Uveitis by Laterality
4.5 Epidemiological Forecast for Uveitis
4.5.1 Diagnosed Incident Cases of Uveitis
4.5.2 Age-Specific Diagnosed Incident Cases of Uveitis
4.5.3 Sex-Specific Diagnosed Incident Cases of Uveitis
4.5.4 Diagnosed Prevalent Cases of Uveitis
4.5.5 Age-Specific Diagnosed Prevalent Cases of Uveitis
4.5.6 Sex-Specific Diagnosed Prevalent Cases of Uveitis
4.5.7 Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation, Etiology, and Severity
4.5.8 Diagnosed Prevalent Cases of Uveitis by Laterality
4.6.1 Epidemiological Forecast Insight
4.6.2 COVID-19 Impact
4.6.3 Limitations of Analysis
4.6.4 Strengths of the Analysis
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 Treatment Guidelines
5.3 Pharmacotherapeutic Management of Non-infectious Uveitis
5.3.1 Anterior Uveitis
5.3.2 Intermediate, Posterior, and Panuveitis
5.4 Marketed Drugs by Therapeutic Class
5.4.3 Antimuscarinic Agents
5.5 Treatment of Uveitis by Geographic Region
5.5.1 North America
5.6 KOL Insights on Disease Management
6 Competitive Assessment
7 Unmet Needs and Opportunity Assessment
7.2 Increasing Disease Awareness Among Physicians and Patients
7.3 Improving the Safety and Side-Effect Profiles of Pharmaceutical Products
7.4 Making Drug Administration More Manageable for Patients
7.5 Standardization of Treatment Guidelines for Different Disease Subtypes
8 R&D Strategies
8.1.1 Innovation in the Uveitis Pipeline
8.1.2 Repurposing Biologic Therapies Marketed for Autoimmune Diseases
8.1.3 Optimizing Administration of Immunosuppressants
8.2 Clinical Trials Design
8.2.1 Primary and Secondary Endpoints
8.2.2 Trial Duration and Steroid-Sparing Treatment Strategies
8.2.3 Uveitis as an Add-On Indication
9 Pipeline Assessment
9.2 Clinical Trials
9.3 Late-Stage Pipeline Products
9.4 Other Drugs in Clinical Development
10 Pipeline Valuation Analysis
10.2 Clinical Benchmarking
10.3 Commercial Benchmarking
10.4 Competitive Assessment
11 Current and Future Players
11.2 Trends in Corporate Strategy
11.3 Deal-Making Trends
11.4 Analysis of Company Portfolios in the Uveitis Market
11.4.1 AbbVie and Allergan
11.5 Analysis of Company Portfolios in the Uveitis Pipeline
11.5.4 Tarsius Pharma
11.5.5 Enzo Biochem
11.5.8 Panoptes Pharma
12 Market Outlook
12.1 Global Markets
12.1.2 Drivers and Barriers – Global Issues
12.2.2 Key Events
12.2.3 Drivers and Barriers
12.3.2 Key Events
12.3.3 Drivers and Barriers
12.4.2 Key Events
12.4.3 Drivers and Barriers
12.5.2 Key Events
12.5.3 Drivers and Barriers
12.6.2 Key Events
12.6.3 Drivers and Barriers
13.3.1 Forecasting Methodology
13.3.2 Diagnosed Patients
13.3.3 Percent Drug-Treated Patients
13.3.4 Drugs Included in Each Therapeutic Class
13.3.5 Clinical Positioning of Marketed Drugs
13.3.6 Clinical Positioning of Pipeline Drugs
13.3.7 General Pricing Assumptions
13.3.8 Pricing of Pipeline Agents
13.4 Primary Research – KOLs Interviewed for This Report
13.5 Primary Research – Prescriber Survey
13.6 About the Authors
13.6.2 Therapy Area Director
13.6.4 Managing Epidemiologist
13.6.5 Global Director of Therapy Analysis and Epidemiology
13.6.6 Global Head and EVP of Healthcare Operations and Strategy
13.7 Contact Us
List of Tables
Table 1: Non-infectious Uveitis: Key Metrics in the 9MM
Table 2: SUN Working Group Anatomical Classification of Uveitis
Table 3: SUN Working Group Classification of Uveitis by Disease Onset and Duration
Table 4: Grading of Anterior Chamber Flare and Anterior Chamber Cells
Table 5: Grading of Vitreous Haze
Table 6: Autoimmune Uveitis and Ocular Complications
Table 7: Risk Factors and Comorbidities for Uveitis
Table 8: Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation, Etiology, and Severity
Table 9: Diagnosed Prevalent Cases of Uveitis by Laterality
Table 10: Treatment Guidelines for Uveitis in the 9MM
Table 11: Uveitis Disease Management – North America
Table 12: Uveitis Disease Management – 5EU
Table 13: Uveitis Disease Management – Japan and Australia
Table 14: Marketed Drugs for Uveitis Across the 9MM
Table 15: Comparison of Therapeutic Classes of Pipeline Drug Candidates for Non-infectious Uveitis, 2019-2029
Table 16: Phase I Pipeline Products in Development for Uveitis
Table 17: AbbVie’s Uveitis Portfolio Assessment, 2021
Table 18: Novartis’ Uveitis Portfolio Assessment, 2021
Table 19: Chugai’s Uveitis Portfolio Assessment, 2021
Table 20: Aciont’s Uveitis Portfolio Assessment, 2021
Table 21: Oculis’ Uveitis Portfolio Assessment, 2021
Table 22: Tarsius Pharma’s Uveitis Portfolio Assessment, 2021
Table 23: Enzo Biochem’s Uveitis Portfolio Assessment, 2021
Table 24: Santen’s Uveitis Portfolio Assessment, 2021
Table 25: Eyevensys’ Uveitis Portfolio Assessment, 2021
Table 26: Panoptes Pharma’s Uveitis Portfolio Assessment, 2021
Table 27: Uveitis Market – Global Drivers and Barriers, 2019-2029
Table 28: Key Events Impacting Sales for Uveitis in the US, 2019-2029
Table 29: Uveitis Market – Drivers and Barriers in the US, 2019-2029
Table 30: Key Events Impacting Sales for Uveitis in the 5EU, 2019-2029
Table 31: Uveitis Market – Drivers and Barriers in the 5EU, 2019-2029
Table 32: Key Events Impacting Sales for Uveitis in Japan, 2019-2029
Table 33: Uveitis Market – Drivers and Barriers in Japan, 2019-2029
Table 34: Key Events Impacting Sales for Uveitis in Canada, 2019-2029
Table 35: Uveitis Market – Drivers and Barriers in Canada, 2019-2029
Table 36: Key Events Impacting Sales for Uveitis in Australia, 2019-2029
Table 37: Uveitis Market – Drivers and Barriers in Australia, 2019-2029
Table 38: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
List of Figures
Figure 1: Global (9MM) Sales Forecast by Geographic Region for Uveitis in 2019 and 2029
Figure 2: Analysis of the Company Portfolio Gap in Uveitis During the Forecast Period
Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Uveitis During the Forecast Period
Figure 4: Differentiation of Pro-inflammatory T-cells in Non-infectious Uveitis
Figure 5: 9MM, Diagnosed Incidence of Uveitis, Men and Women, Cases Per 100,000 Population, Ages ≥18 Years, 2019
Figure 6: 9MM, Diagnosed Prevalence of Uveitis, Men and Women, %, Ages ≥18 Years, 2019
Figure 7: 9MM, Sources Used and Not Used to Forecast the Diagnosed Incident and Diagnosed Prevalent Cases of Uveitis
Figure 8: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Anatomical Site of Inflammation
Figure 9: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Etiology
Figure 10: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Severity
Figure 11: 9MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Uveitis by Laterality
Figure 12: 9MM, Diagnosed Incident Cases of Uveitis, N, Both Sexes, Ages ≥18 Years, 2019
Figure 13: 9MM, Diagnosed Incident Cases of Uveitis by Age, N, Both Sexes, 2019
Figure 14: 9MM, Diagnosed Incident Cases of Uveitis by Sex, N, Ages ≥18 Years, 2019
Figure 15: 9MM, Diagnosed Prevalent Cases of Uveitis, N, Both Sexes, Ages ≥18 Years, 2019
Figure 16: 9MM, Diagnosed Prevalent Cases of Uveitis by Age, N, Both Sexes, 2019
Figure 17: 9MM, Diagnosed Prevalent Cases of Uveitis by Sex, N, Ages ≥18 Years, 2019
Figure 18: Unmet Needs and Opportunities in Uveitis
Figure 19: Snellen Chart Used to Measure Visual Acuity in Patients With Uveitis
Figure 20: Overview of the Development Pipeline in Uveitis
Figure 21: Key Ongoing Clinical Trials Involving Patients With Non-infectious Uveitis in the 9MM
Figure 22: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Uveitis During the Forecast Period
Figure 23: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Ocular Application, Pred Forte
Figure 24: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Systemic Treatment, Humira
Figure 25: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC Intraocular Preparation, Ozurdex
Figure 26: Analysis of the Company Portfolio Gap in Uveitis During the Forecast Period
Figure 27: Global (9MM) Sales Forecast by Geographic Region for Uveitis in 2019 and 2029
Figure 28: Sales of Corticosteroids for Uveitis in the 9MM, 2019 and 2029
Figure 29: Sales Forecast by Therapeutic Class for Uveitis in the 9MM, 2019 and 2029
Figure 30: Sales Forecast by Therapeutic Class for Uveitis in the US in 2019 and 2029
Figure 31: Sales Forecast by Therapeutic Class for Uveitis in the 5EU in 2019 and 2029
Figure 32: Sales Forecast by Therapeutic Class for Uveitis in Japan in 2019 and 2029
Figure 33: Sales Forecast by Therapeutic Class for Uveitis in Canada in 2019 and 2029
Figure 34: Sales Forecast by Therapeutic Class for Uveitis in Australia in 2019 and 2029